Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free JSPRW Stock Alerts

Jasper Therapeutics (JSPRW) Competitors

Jasper Therapeutics logo
$0.01 0.00 (0.00%)
As of 07/21/2026
Compare

JSPRW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Jasper Therapeutics compare to Ainos?

Jasper Therapeutics (NASDAQ:JSPRW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

In the previous week, Jasper Therapeutics had 2 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Ainos. Jasper Therapeutics' average media sentiment score of 0.30 beat Ainos' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Neutral
Ainos Neutral

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

Summary

Jasper Therapeutics beats Ainos on 2 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to Alvotech?

Jasper Therapeutics (NASDAQ:JSPRW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Alvotech. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Alvotech. Jasper Therapeutics' average media sentiment score of 0.30 beat Alvotech's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Neutral
Alvotech Neutral

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

Summary

Jasper Therapeutics beats Alvotech on 2 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and Jasper Therapeutics (NASDAQ:JSPRW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Aravive. Jasper Therapeutics' average media sentiment score of 0.30 beat Aravive's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Jasper Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

Summary

Aravive and Jasper Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does Jasper Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Jasper Therapeutics (NASDAQ:JSPRW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

In the previous week, Jasper Therapeutics had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Jasper Therapeutics' average media sentiment score of 0.30 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Summary

Jasper Therapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Jasper Therapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Jasper Therapeutics (NASDAQ:JSPRW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Jasper Therapeutics had 2 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Biofrontera. Jasper Therapeutics' average media sentiment score of 0.30 beat Biofrontera's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Jasper Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

Summary

Jasper Therapeutics beats Biofrontera on 2 of the 3 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPRW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPRW vs. The Competition

Export
MetricJasper TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$528.46M$7.01B$12.68B
Dividend YieldN/A3.90%2.67%9.42%
P/E RatioN/A3.4926.8823.95
Price / SalesN/A6,282.29518.3593.75
Price / CashN/A13.1350.6060.45
Price / BookN/A87.6810.566.16
Net IncomeN/A-$96.07M$3.60B$331.73M
7 Day PerformanceN/A-0.56%-2.15%-1.96%
1 Month PerformanceN/A0.11%0.10%-2.49%
1 Year PerformanceN/A56.20%22.55%17.21%

Jasper Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPRW
Jasper Therapeutics
N/A$0.01
flat		N/A-87.1%$0.00N/AN/A20
AIMDW
Ainos
N/A$0.10
-20.6%		N/A-37.5%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.17
flat		N/A-90.6%$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JSPRW) was last updated on 7/22/2026 by MarketBeat.com Staff.
From Our Partners
America’s answer to universal basic income
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon is about to dominate the biggest arms race in tech history
Microsoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...
The Oxford Club | Sponsoredtc pixel
Wall Street legend put 60% in one stock — here’s the ticker
One of America's most famous investors put 60% of his fund into a single stock - and Whitney Tilson of Stansbe...
Stansberry Research | Sponsoredtc pixel
It all happens tonight.
Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...
Trade Thirsty | Sponsoredtc pixel
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel